STEMCELLS INC Form 8-K October 28, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	October 28, 2010
---	------------------

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
3155 Porter Drive, Palo Alto, California		94304
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area	code:	650.475.3100
	Not Applicable	
Former name or	former address, if changed since	last report
Check the appropriate box below if the Form 8-K filing is i	intended to simultaneously satisfy	the filing obligation of the registrant under any of
the following provisions:		
[] Written communications pursuant to Rule 425 under th	ne Securities Act (17 CFR 230.42	5)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form Item 8.01 Other Events.

On October 28, 2010, StemCells, Inc. announced that it has initiated a second clinical trial of its HuCNS-SC® product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease). The full text of this press release is attached hereto as Exhibit 99.1.

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

October 28, 2010 By: /s/ Kenneth Stratton

Name: Kenneth Stratton Title: General Counsel

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release of StemCells, Inc. dated October 28, 2010